Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of apatinib combined with etoposide in recurrent ovarian, fallopian tube, and primary peritoneal cancer
ChiCTR1900022376Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- May 2019
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib and etoposide in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoints: Overall survival, Time to progression and 2 more. Planned start May 2019; status: not yet recruiting.
02
Drugs
Rivoceranibetoposide
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR1900022376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022376.